Anatomical main group
J – ANTIINFEKTIVA ZUR SYSTEMISCHEN ANWENDUNG
93Decisions
227Patient groups
Added benefit by patient group
- Considerable20
- Minor22
- Non-quantifiable21
- Deemed proven35
- Not proven129
Subgroups
- J01 ANTIBIOTIKA ZUR SYSTEMISCHEN ANWENDUNG 14 decisions
- J02 ANTIMYKOTIKA ZUR SYSTEMISCHEN ANWENDUNG 4 decisions
- J04 MITTEL GEGEN MYKOBAKTERIEN 4 decisions
- J05 ANTIVIRALE MITTEL ZUR SYSTEMISCHEN ANWENDUNG 63 decisions
- J06 IMMUNSERA UND IMMUNGLOBULINE 8 decisions
Decisions, newest first
- 2026-08-06RecarbrioImipenem/Cilastatin/RelebactamDeemed proven: 3 of 3 patient groups
- 2026-07-16XeravaEravacyclinDeemed proven
- 2026-06-04PaxlovidNirmatrelvir/RitonavirNot proven
- 2026-02-19HepcludexBulevirtidNot proven: 2 of 2 patient groups
- 2026-01-22VekluryRemdesivirNot proven
- 2025-11-20XydalbaDalbavancinDeemed proven
- 2025-11-06PrevymisLetermovirNot proven
- 2025-11-06PrevymisLetermovirNon-quantifiable
- 2025-08-21BeyfortusNirsevimabConsiderable
- 2025-08-07KavigaleSipavibartNot proven: 2 of 2 patient groups
- 2025-08-07VocabriaCabotegravirNot proven
- 2025-05-15ZaviceftaCeftazidim/AvibactamDeemed proven: 4 of 4 patient groups
- 2025-04-17VaboremMeropenem/VaborbactamDeemed proven: 5 of 5 patient groups
- 2025-03-20CresembaIsavuconazolNon-quantifiable
- 2025-03-20CresembaIsavuconazolNon-quantifiable
- 2025-02-20BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2024-12-05ExblifepCefepim/EnmetazobactamDeemed proven: 3 of 3 patient groups
- 2024-08-15BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2024-08-01RezzayoRezafunginNon-quantifiable
- 2024-06-06PrevymisLetermovirNon-quantifiable
- 2024-06-06PrevymisLetermovirNot proven
- 2024-02-01XydalbaDalbavancinDeemed proven
- 2024-02-01SirturoBedaquilinConsiderable
- 2023-11-02EvusheldTixagevimab/CilgavimabNot proven
- 2023-08-17TriumeqDolutegravir/Abacavir/LamivudinNot proven: 3 of 3 patient groups
- 2023-06-15BiktarvyBictegravir/Emtricitabin/TenofoviralafenamidNot proven: 4 of 4 patient groups
- 2023-06-01LivtencityMaribavirMinor
- 2023-04-20GenvoyaElvitegravir/Cobicistat/Emtricitabin/TenofoviralafenamidNot proven: 2 of 2 patient groups
- 2023-04-20EvusheldTixagevimab/CilgavimabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-04-06VekluryRemdesivirNot proven
- 2023-04-06VekluryRemdesivirNot proven
- 2023-02-02ZerbaxaCeftolozan/TazobactamDeemed proven: 3 of 3 patient groups
- 2023-01-19XeravaEravacyclinDeemed proven
- 2022-12-15PaxlovidNirmatrelvir/RitonavirConsiderable
- 2022-11-03XevudySotrovimabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-11-03ZaviceftaCeftazidim/AvibactamDeemed proven: 5 of 5 patient groups
- 2022-11-03ZerbaxaCeftolozan/TazobactamDeemed proven: 4 of 4 patient groups
- 2022-11-03RecarbrioImipenem/Cilastatin/RelebactamDeemed proven: 3 of 3 patient groups
- 2022-10-20PifeltroDoravirinNot proven: 2 of 2 patient groups
- 2022-10-20DelstrigoDoravirin/Lamivudin/TenofovirdisoproxilNot proven
- 2022-08-04EpclusaSofosbuvir/VelpatasvirNot proven
- 2022-07-07VekluryRemdesivirMinor
- 2022-05-05ZepatierElbasvir/GrazoprevirNot proven
- 2022-05-05DeltybaDelamanidNon-quantifiable: 2 of 2 patient groups
- 2022-05-05FetcrojaCefiderocolDeemed proven
- 2022-04-07VoseviSofosbuvir/Velpatasvir/VoxilaprevirNot proven
- 2021-12-16MaviretGlecaprevir/PibrentasvirNot proven: 2 of 2 patient groups
- 2021-10-21RekambysRilpivirinNot proven
- 2021-10-21VocabriaCabotegravirNot proven
- 2021-09-16SirturoBedaquilinNon-quantifiable
- 2021-09-16VekluryRemdesivirMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-09-16RukobiaFostemsavirNot proven
- 2021-08-05XofluzaBaloxavir marboxilConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-08-05XofluzaBaloxavir marboxilNot proven: 2 of 2 patient groups
- 2021-07-15TivicayDolutegravirNot proven: 2 of 2 patient groups
- 2021-05-20Arikayce liposomalAmikacinNon-quantifiable
- 2021-04-01EpclusaSofosbuvir/VelpatasvirNot proven: 4 of 4 patient groups
- 2021-01-21HarvoniLedipasvir/SofosbuvirNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-01-21SovaldiSofosbuvirNon-quantifiable
- 2020-08-20SirturoBedaquilinNon-quantifiable
- 2020-02-06DovatoDolutegravir/LamivudinNot proven: 4 of 4 patient groups
- 2019-10-17MaviretGlecaprevir/PibrentasvirNot proven: 2 of 2 patient groups
- 2019-07-04DelstrigoDoravirin/Lamivudin/TenofovirdisoproxilNot proven: 2 of 2 patient groups
- 2019-07-04PifeltroDoravirinNot proven: 2 of 2 patient groups
- 2019-03-22VemlidyTenofoviralafenamidNot proven: 4 of 4 patient groups
- 2018-12-20BiktarvyBictegravir/Emtricitabin/TenofoviralafenamidNot proven: 2 of 2 patient groups
- 2018-12-06JulucaDolutegravir/RilpivirinNot proven
- 2018-09-20ZinplavaBezlotoxumabMinor
- 2018-07-05GenvoyaElvitegravir/Cobicistat/Emtricitabin/TenofoviralafenamidNot proven: 2 of 2 patient groups
- 2018-05-03StribildElvitegravir/Cobicistat/Emtricitabin/TenofovirdisoproxilNot proven
- 2018-04-05SovaldiSofosbuvirNon-quantifiable: 2 of 2 patient groups
- 2018-03-16SymtuzaDarunavir/Cobicistat/Emtricitabin/TenofoviralafenamidNot proven: 4 of 4 patient groups
- 2018-02-15HarvoniLedipasvir/SofosbuvirNon-quantifiable: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2018-02-15VoseviSofosbuvir/Velpatasvir/VoxilaprevirNot proven: 6 of 6 patient groups
- 2018-02-01MaviretGlecaprevir/PibrentasvirNot proven: 7 of 7 patient groups
- 2017-09-21TivicayDolutegravirNot proven: 2 of 2 patient groups
- 2017-06-15ZepatierElbasvir/GrazoprevirNot proven: 2 of 2 patient groups
- 2017-01-05OdefseyEmtricitabin/Rilpivirin/TenofoviralafenamidNot proven: 4 of 4 patient groups
- 2017-01-05EpclusaSofosbuvir/VelpatasvirConsiderable: 1 of 9 patient groupsMinor: 1 of 9 patient groupsNon-quantifiable: 1 of 9 patient groupsNot proven: 6 of 9 patient groups
- 2016-11-03DescovyEmtricitabin/TenofoviralafenamidNot proven: 4 of 4 patient groups
- 2016-06-16EdurantRilpivirinNot proven
- 2016-06-16GenvoyaElvitegravir/Cobicistat/Emtricitabin/TenofoviralafenamidNot proven: 4 of 4 patient groups
- 2016-05-04CresembaIsavuconazolNon-quantifiable: 2 of 2 patient groups
- 2015-07-16ViekiraxOmbitasvir/Paritaprevir/RitonavirConsiderable: 4 of 9 patient groupsMinor: 4 of 9 patient groupsNot proven: 1 of 9 patient groups
- 2015-07-16ExvieraDasabuvirConsiderable: 4 of 7 patient groupsMinor: 3 of 7 patient groups
- 2015-05-21HarvoniLedipasvir/SofosbuvirConsiderable: 3 of 7 patient groupsMinor: 1 of 7 patient groupsNon-quantifiable: 2 of 7 patient groupsNot proven: 1 of 7 patient groups
- 2015-03-19TriumeqDolutegravir/Abacavir/LamivudinConsiderable: 1 of 5 patient groupsNot proven: 4 of 5 patient groups
- 2014-08-07TivicayDolutegravirConsiderable: 1 of 5 patient groupsMinor: 1 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2014-07-17SovaldiSofosbuvirConsiderable: 1 of 9 patient groupsMinor: 5 of 9 patient groupsNot proven: 3 of 9 patient groups
- 2014-06-19EvipleraEmtricitabin/Rilpivirin/TenofovirdisoproxilNot proven
- 2013-12-05StribildElvitegravir/Cobicistat/Emtricitabin/TenofovirdisoproxilNot proven: 2 of 2 patient groups
- 2012-07-05EdurantRilpivirinMinor
- 2012-07-05EvipleraEmtricitabin/Rilpivirin/TenofovirdisoproxilMinor
Data status: 2026-10-29